| The state-of-play and future of antibody therapeutics Z Elgundi, M Reslan, E Cruz, V Sifniotis, V Kayser Advanced drug delivery reviews 122, 2-19, 2017 | 336 | 2017 |
| Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation V Sifniotis, E Cruz, B Eroglu, V Kayser Antibodies 8 (2), 36, 2019 | 76 | 2019 |
| Benzimidazolium-based novel silver N-heterocyclic carbene complexes: synthesis, characterisation and in vitro antimicrobial activity Y Sarı, S Akkoç, Y Gök, V Sifniotis, İ Özdemir, S Günal, V Kayser Journal of Enzyme Inhibition and Medicinal Chemistry 31 (6), 1527-1530, 2016 | 37 | 2016 |
| Enhancing the stability of adalimumab by engineering additional glycosylation motifs M Reslan, V Sifniotis, E Cruz, Z Sumer-Bayraktar, V Kayser International journal of biological macromolecules 158, 189-196, 2020 | 14 | 2020 |
| Laboratory scale production and purification of a therapeutic antibody Z Elgundi, V Sifniotis, M Reslan, E Cruz, V Kayser JoVE (Journal of Visualized Experiments), e55153, 2017 | 11 | 2017 |
| Glycan profile analysis of engineered trastuzumab with rationally added glycosylation sequons presents significantly increased glycan complexity E Cruz, V Sifniotis, Z Sumer-Bayraktar, M Reslan, L Wilkinson-White, ... Pharmaceutics 13 (11), 1747, 2021 | 2 | 2021 |
| Establishment and Application of Engineered NIH 3T3 Cell Line with Stable Human RAGE Expression X Xiao, H Chen, P Paerhati, M Zhou, Z Yang, S Bai, Y Yuan Pharmaceutical Fronts 2 (01), e23-e27, 2020 | | 2020 |
| Towards The Development of Biobetter Therapeutic Whole Antibodies V Sifniotis | | 2019 |
